On Monday, February 25, 2008, at 8:30am EST, the Company will host an investor conference call during which they will provide a brief financial overview of the Company's fourth quarter and year-end 2007 financial results and business outlook for 2008.
In order to participate in the conference call, please call 1-877-874-1565 (U.S.), 1-719-325-4750 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition,
development and commercialization of medically important, novel
pharmaceutical products for the treatment of life-threatening diseases,
including diabetes and cancer. Keryx's lead compound under development is
Sulonex(TM) (sulodexide) oral gelcaps, previously referred to as KRX-101, a
first-in-class, oral heparinoid compound for the treatment of diabetic
nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex
is in a pivotal Phase 3 and Phase 4 clinical program under a Special
Protocol Assessment with the Food & Drug Administration. Additionally,
Keryx is developing Zerenex(TM), an oral, iron- based compound that has the
capacity to bind phosphate and form non-absorbable complexes. Zerenex is
currently in Phase 2 clinical development for the treatment of
hyperphosphatemia (elevated serum phosphorous levels) in patients with end-
stage renal disease. Keryx is also developing clinical-stage oncology
compounds, including KRX-0401 (perifosine), a novel, oral anti-cancer agent
that modulates Akt, a protein in the body associated with tumor survival
and growth. KRX-0401 also modulates a number of other key signal
|SOURCE Keryx Biopharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved